Cardiac issues related to trastuzumab

Breast

Volumn 13, Issue 3, 2004, Pages 171-172

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; EDITORIAL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 3242665208     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.02.008     Document Type: Editorial

References (8)

1. Marty M. Baselga J. Gatzemeier U. et al Pooled analysis of sic trials of trastuzumab (Herceptin): exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events Breast Cancer Res Treat 82 Suppl 1 2003 S48
2. Washington CB, Flexner C, Sheiner LB, et al. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clin Pharmacol Ther 2003;73(5).
3. Ghahramani P. Barton C. Leyland-Jones B.et al. Pharmacokinetics of herceptin administered three-weekly compared to weekly-a simulation based on data from the clinical studies The Breast 12 Suppl 1 2003 S40
4. Cabonell-Castellon X, Castaneda-Soto NJ, Clemens M, et al. Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study Proc Am Soc Clin Oncol 21 2002 19a
5. Leyland-Jones B. Gelmon K. Ayoub J.P. et al Pharmacokinetics, Safety, and Efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 21 2003 3965-3971
6. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer Oncology 61 Suppl 2 2001 58-60
7. Perez E.A. Rodeheffer R. Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 2 2004 322-329
8. ® in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC) Breast Cancer Res Treat 82 suppl 1 2003 S13